U.S Department of Transportation proposed to modify its current drug testing program regulation to include these new opioids: oxycodone, hydromorphone, hydrocodone and oxymorphone. Also, DOT proposes to eliminate methylenedioxymethamphetamine (MDEA) for confirmatory test analyte and adding methylenedioxyamphetamine (MDA) for initial test analyte.
DOT’s purpose is to line up its drug regulated industry testing with the same requirements as the Department of Health and Human Services. DOT affirmed that its Notice of Proposed Rulemaking, published in the Federal Register last Jan. 23th, will clarify some actual drug testing provisions, eliminate current obsolete regulation information, as well as the condition for C/TPAS and of employers submitting blind samples.
Furthermore, DOT informed some others aspects of the proposal:
- Eliminate blind sample testing
- Change various provisions regarding urine specimens
- Eliminate, or change and include particular definitions and make specific definitions coherent with those of U.S. Department of Health and Human Services
- Include an explanation to the term “prescription”
- Alter sections associated to how MROs check test results connected to semi synthetic opioids.
- Give special emphasis to an existent Part 40 provision, which bans DNA testing based on urine specimens
DOT pointed out that the Omnibus Transportation Employees Testing Act requires compliance with HHS conditions for the testing protocols/procedures and drugs, for which it tests.